Moderna Stock Takes Off After Good News for Its Birth-Defect Vaccine

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

We are a not for profit Independent Media Group, which survives off donations. Even as little as $5 per month, from our generous readers. Please donate now, to help fund our work.

By : Josh Nathan-Kazis

Shares of the biotech company Moderna are jumping on news of progress on the company’s vaccine for cytomegalovirus, a disease that can lead to birth defects. Moderna shares were trading up 9.3% on Friday morning, at $20.12.

After the market closed Thursday, Moderna (ticker: MRNA) announced positive interim data on the Phase 1 trial of its CMV vaccine, and said it had dosed its first patient in the vaccine’s Phase 2 trial.

On an investor call Friday morning, Moderna CEO Stéphane Bancel said that the company estimates peak sales of the CMV vaccine of between $2 billion and $5 billion.

“We believe our CMV vaccine now has a very high probability of success to launch,” Bancel said on the call.

As Barron’s wrote Thursday afternoon, the initiation of the Phase 2 trial marks the start of the first-ever Phase 2 clinical trial for a vaccine for infectious disease based on messenger RNA, the modality in which Moderna specializes.

In an August cover story, Barron’s profiled Moderna’s effort to use mRNA to build vaccines, cancer treatments, and other mRNA-based cures. Prophylactic vaccines represent the most scientifically straightforward of the implementations of the technology and are at the front of Moderna’s pipeline. The company so far has no drugs on the market. It went public in December 2018 in a blockbuster $604 million IPO.

Yet some uncertainty remains around Moderna, which has yet to advance any of its programs to Phase 3 clinical trials. Shares of Moderna soared in early 2019 but fell sharply last spring and summer. The stock ended 2019 up 24.8% on the year, sticking close to the performance of the iShares Nasdaq Biotechnology exchange-traded fund (IBB), which was up 24.9% over the same period.

In its announcement on Thursday, Moderna said that patients in its Phase 1 trial of the CMV vaccine showed a higher volume of antibodies in their blood after their third dose of their vaccine than after their second.

The Phase 2 study will include 252 healthy adults. It is designed to select the appropriate dosing for the Phase 3 study, which will include up to 8,000 patients. The company hopes to start it next year, Moderna’s chief medical officer, Tal Zaks, said on the investor call.

“We are already starting to prepare the Phase 3, but we’re also starting to recruit marketing and commercial talent to prepare prelaunch commercial activities during the Phase 3,” Bancel said on the Friday call. “We believe that infectious-disease vaccines will be an important backbone for growth and cash-flow generation for Moderna, and the CMV vaccine will be a franchise builder.”

*Note We Deliberately Miss Spell Some Words or Add Capital Letters To Get Around Big Tech Censoring.

Support the ANR from as little as $50 – it only takes a minute. If you can, please consider supporting us with a regular amount each month. Thank you.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

Related News

Truthbook.social offering hundreds of thousands in giveaways for those joining its new social media platform as many desert Facebook in droves because of censoring

Here is some of the current incentives being offered to new users

Subscribe for free to our ANR news emails and access 2 free ebooks plus Reports to share with family and friends about Covid fraud and the danger of the vaccines.

For ANR Smaller Donors please donate below to help fund our critical not for profit work. Together we can defeat mainstream media.

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset.

and help us expose the Covid Fraudsters

Leave a Reply

Your email address will not be published.

Play Video

McIntyre Report
Political Talk Show

How you can advertise on Truthbook.social

Jamie McIntyre
TruthBook.social Videos

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset.

and help us expose the Covid Fraudsters

Ukraine. Military Summary And Analysis 17.08.2022

Raw Report

Ryan Jackson Saw show

in USD

in AUD

in GBP

in CAD

Jamie McIntyre

ANR on

Currency Exchange Rates in AUD

Live and updated every minute of the day

Nurses Speak Out

Get our free News Emails on latest articles, alerts and solutions for both legal templates and ways to help fight back against the Globalists vax Mandates , and health resources to boost your immune system and ways to Protect from deadly EMF 5G radiation and more.

FREE E-BOOKS AND REPORTS ALSO

ANR Meme Report

with Nadine Roberts

Episode 002

21st Century Political System

Play Video

Editor's Pick

Thank you for visiting the
Australian National Review

To continue accessing more articles for free simply enter your email address

We are only 27% funded for next month's operations.

ANR is fully funded by our readers, people like you who often can’t stand mainstream media lies and propaganda. So please help us continue exposing the truth and helping defeat the Globalists and defend your and your children’s futures.

Help us help defend free speech and save democracy from the World Economic Forum planned Totalitarian Great Reset and help us expose the Covid Fraudsters

just $5 a month helps

Download the Full PDF - THE COVID-19 FRAUD & WAR ON HUMANITY